Taha Merghoub
Taha Merghoub
Associate Professor, MSK
Verified email at - Homepage
Cited by
Cited by
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ...
Science 348 (6230), 124-128, 2015
Genetic basis for clinical response to CTLA-4 blockade in melanoma
A Snyder, V Makarov, T Merghoub, J Yuan, JM Zaretsky, A Desrichard, ...
New England Journal of Medicine 371 (23), 2189-2199, 2014
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ...
Science 351 (6280), 1463-1469, 2016
Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses
KB Chiappinelli, PL Strissel, A Desrichard, H Li, C Henke, B Akman, ...
Cell 162 (5), 974-986, 2015
Neoadjuvant PD-1 blockade in resectable lung cancer
PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ...
New England Journal of Medicine 378 (21), 1976-1986, 2018
Molecular determinants of response to anti–programmed cell death (PD)-1 and anti–programmed death-ligand 1 (PD-L1) blockade in patients with non–small-cell lung cancer profiled …
H Rizvi, F Sanchez-Vega, K La, W Chatila, P Jonsson, D Halpenny, ...
Journal of clinical oncology 36 (7), 633, 2018
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
SA Quezada, TR Simpson, KS Peggs, T Merghoub, J Vider, X Fan, ...
Journal of Experimental Medicine 207 (3), 637-650, 2010
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
VP Balachandran, M Łuksza, JN Zhao, V Makarov, JA Moral, R Remark, ...
Nature 551 (7681), 512-516, 2017
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy
D Zamarin, RB Holmgaard, SK Subudhi, JS Park, M Mansour, P Palese, ...
Science translational medicine 6 (226), 226ra32-226ra32, 2014
Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
MD Hellmann, T Nathanson, H Rizvi, BC Creelan, F Sanchez-Vega, ...
Cancer cell 33 (5), 843-852. e4, 2018
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
O De Henau, M Rausch, D Winkler, LF Campesato, C Liu, DH Cymerman, ...
Nature 539 (7629), 443-447, 2016
Chromatin states define tumour-specific T cell dysfunction and reprogramming
M Philip, L Fairchild, L Sun, EL Horste, S Camara, M Shakiba, AC Scott, ...
Nature 545 (7655), 452-456, 2017
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas
P Lito, CA Pratilas, EW Joseph, M Tadi, E Halilovic, M Zubrowski, ...
Cancer cell 22 (5), 668-682, 2012
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression
T Maeda, RM Hobbs, T Merghoub, I Guernah, A Zelent, C Cordon-Cardo, ...
Nature 433 (7023), 278-285, 2005
Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
JC Osorio, A Ni, JE Chaft, R Pollina, MK Kasler, D Stephens, C Rodriguez, ...
Annals of Oncology 28 (3), 583-589, 2017
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ...
Nature 551 (7681), 517-520, 2017
Emerging concepts for immune checkpoint blockade-based combination therapies
R Zappasodi, T Merghoub, JD Wolchok
Cancer cell 33 (4), 581-598, 2018
Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner
RB Holmgaard, D Zamarin, Y Li, B Gasmi, DH Munn, JP Allison, ...
Cell reports 13 (2), 412-424, 2015
Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient
A Jiménez-Sánchez, D Memon, S Pourpe, H Veeraraghavan, Y Li, ...
Cell 170 (5), 927-938. e20, 2017
Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor MicroenvironmentGM-CSF–Activated CCR2+ MDSCs …
AM Lesokhin, TM Hohl, S Kitano, C Cortez, D Hirschhorn-Cymerman, ...
Cancer research 72 (4), 876-886, 2012
The system can't perform the operation now. Try again later.
Articles 1–20